Differences in prognosis and efficacy of chemotherapy by p53 expression in triple-negative breast cancer.

doi:10.1007/s10549-018-4928-2

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Back to search

Article

Differences in prognosis and efficacy of chemotherapy by p53 expression in triple-negative breast cancer.

Breast cancer research and treatment - 1 Nov 2018

Bae Soo Youn, Nam Seok Jin, Jung Yongsik, Lee Sae Byul, Park Byung-Woo, Lim Woosung, Jung Sung Hoo, Yang Hsien Wen, Jung Seung Pil

Abstract excerpt

PURPOSE: TP53 mutation is the most common mutation in breast cancer, and it is considered a target marker of triple-negative breast cancer (TNBC). We investigated whether expression of p53 detected by immunochemical staining predicts the chemotherapy response of TNBC. METHODS: A total of 11,393 TNBC patients who had between stage I and stage III enrolled in the Korean Breast Cancer Society Registry database from...

Topics

Adult
Aged
Biomarkers, Tumor
Chemotherapy, Adjuvant
Disease-Free Survival
Female
Humans
Middle Aged
Mutation
Prognosis
Triple Negative Breast Neoplasms
Tumor Suppressor Protein p53

Source

Open in PubMed

Identifiers

PMID: 30132220
DOI: 10.1007/s10549-018-4928-2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 30 Aug 2026.

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

discussions

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics